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General: All reactions were carried out under a nitrogen atmosphere in oven- or flame-dried 
glassware. Dibutylboron triflate (1.0 M solution in dichloromethane) was purchased from 
Aldrich Chemical Co. and was used as obtained. All imines and α-amido sulfones were prepared 
from aldehydes obtained from commercial sources (Aldrich Chemical Co. or Acros Chemical 
Co.). Aldehydes were purified by distillation from crushed anhydrous Ca2SO4. Triethylamine and 
diisopropylethylamine were obtained from Aldrich Chemical Co. and were purified by 
distillation from CaH2. Phosphate buffer solution (pH 7) and 2-(benzyloxy)acetyl chloride were 







2’-(benzyloxy)acetate,6 and (–)-(1R,2S)-2-phenylcyclohexyl-2’-(allyloxy)acetate6 were prepared 
according to published procedures. Methylene chloride, tetrahydrofuran, and ether were purified 
using a GlassContour solvent purification system. Yields refer to isolated yields of compounds 
estimated to be ≥95% pure as determined by 1H NMR, GC, and/or combustion analysis. The 
yields reported in the Supporting Information describe the result of a single experiment, whereas 
the yields reported in Tables 1–3 and eq 2–6 are average yields of two or more experiments. 
Thus, the yields reported in the Supporting Information may differ from those shown in Tables 
1–3 and eq 2–6. 
  
General Procedure A: Tandem Wittig rearrangement/Mannich reactions. A flame-dried 
flask was cooled under a stream of nitrogen and charged with a 1 M solution of dibutylboron 
triflate in dichloromethane (4.0 equiv). The pale yellow solution was cooled to 0 °C, and 
triethylamine or diisopropylethylamine (3.2 equiv) was added dropwise to afford a colorless 
solution. A solution of the ester substrate (1 equiv) in CH2Cl2 (1 mL/mmol substrate) was then 
added dropwise, and the reaction mixture was warmed to rt, stirred for 15 min (with 
triethylamine as base) or 20 min (with diisopropylethylamine as base), and then cooled to 0 °C. 
A solution of the imine (1.5 or 2 equiv) or α-amido sulfone (2 equiv) in CH2Cl2 (1 mL/mmol 
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substrate) was added dropwise, and the reaction mixture was warmed to rt and stirred for 3–12 h. 
The reaction vessel was then opened to air, and pH 7 buffer (1 mL/0.1 mmol substrate), and 
methanol (2 mL/0.1 mmol substrate) were added. The resulting mixture was cooled to 0 °C, 30% 
aqueous H2O2 (2 mL/0.1 mmol substrate) was added slowly, and the reaction mixture was 
warmed to rt and stirred for 1 h. The mixture was diluted with ether (10 mL/0.1 mmol substrate) 
and water (5 mL/0.1 mmol substrate), then was transferred to a separatory funnel. The layers 
were separated, and the organic layer was washed with a saturated aqueous solution of FeSO4 (4 
x 5 mL/0.1 mmol substrate) until a red-orange aqueous phase no longer persisted in order to 
quench any remaining peroxide. Caution! This procedure is exothermic. The FeSO4 solution 
should be added via glass pipette SLOWLY DROPWISE. The organic layer was then washed 
with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude 
















General Procedure B: Method to Assess Enantiopurity of Products via Conversion to 
Methyl Esters (19, S1, S3).  In order to assess the enantiomeric purity of the products formed in 
the tandem Wittig-rearrangement/Mannich reactions, the 2-phenylcyclohexyl esters 4–5, and 7 
were converted to the corresponding methyl esters 19, S1 and S3 using the following procedure. 
The glycolate ester (1.0 equiv) was dissolved in methanol (0.1 M) and added to a flame-dried 2-
neck flask fitted with a reflux condenser under nitrogen. A solution of NaOMe (4.0 M in MeOH) 
was added, and the reaction mixture was heated to reflux and stirred until the starting material 
had been completely consumed as judged by TLC analysis (ca. 2 h). The reaction mixture was 
cooled to rt, quenched with 1 M HCl (1 mL/0.1 mmol substrate) and concentrated in vacuo. The 
crude residue was diluted with H2O (1 mL/0.1 mmol substrate), and extracted with Et2O (3 x 2 
mL/0.1 mmol substrate). The phases were separated, and the combined organic layers were dried 
over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude methyl ester 
product was purified by flash chromatography on silica gel. The enantiopurity was subsequently 
determined by chiral HPLC analysis. 
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For purposes of comparison, racemic amino-alcohol methyl esters were prepared from the 
corresponding O-benzyl or O-allyl methyl esters,7 using a procedure identical to that described 
























General Procedure C: Method to Assess Enantiopurity of Products (S4, S4–S12) via 
Reduction to Triol and Conversion to Mosher Ester. In order to assess the enantiomeric 
purity of the products formed in the tandem Wittig-rearrangement/Mannich reactions, the 2-
phenylcyclohexyl esters 6, 8–11, 13–14, and 16–18 were converted to the corresponding Mosher 
esters S2, and S4–S12 using the following procedure. The glycolate ester (1.0 equiv) was 
dissolved in THF (0.1 M) and cooled to 0 °C. A solution of LiAlH4 (2 equiv/mmol substrate, 1.0 
M in THF) was added, the reaction mixture was warmed to rt, and stirred until the starting 
material had been completely consumed as judged by TLC analysis. The reaction mixture was 
cooled to 0 °C and quenched with H2O (1 mL/0.1 mmol substrate). The crude residue was 
diluted with Et2O (2 mL/0.1 mmol substrate), 10 M NaOH was added (1 mL/0.1 mmol 
substrate), then H2O (0.5 mL/0.1 mmol substrate) was added. The phases were separated, the 
inorganic precipitate was washed with ether (3 x 2 mL), and the combined organic layers were 
dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The crude triol product 
was purified by flash chromatography on silica gel.  
A solution of the triol in CH2Cl2 (0.2 M), DCC (1.1 equiv), DMAP (0.2 equiv) and (–)-(S)-
3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid (1.1 equiv) were combined and stirred at room 
temperature until the triol had been completely consumed as judged by TLC analysis. The 
reaction mixture was diluted with CH2Cl2, filtered through a cotton plug, and concentrated in 
vacuo. The crude product was purified by flash chromatography on silica gel. The enantiopurity 
was subsequently determined by 19F NMR analysis. 
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For purposes of comparison, racemic amino-alcohol Mosher esters were prepared from the 
corresponding O-benzyl or O-allyl methyl esters,7 using a procedure identical to that described 











phenylpropanoate (4). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(benzyloxy)acetate 
(3a) (47 mg, 0.14 mmol) with N-(benzylidene)benzylamine1 (42 mg, 0.22 mmol) was conducted 
according to General Procedure A using triethylamine as base to afford 54 mg (72%) of the title 
compound as a white foam. The diastereoselectivity of the transformation could not be 
determined through 1H NMR analysis of the crude reaction mixture prior to purification due to 
signal overlap with boron-containing byproducts; the isolated product was obtained with >20:1 
dr following purification. [α]23D –36.8 (c 0.20, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.23–7.24 
(m, 8 H), 7.21–7.14 (m, 6 H), 7.13–7.11 (m, 3 H), 7.08–7.05 (m, 3 H), 4.81–4.76 (m, 1 H), 3.48 
(s, 1 H), 3.30 (s, 1 H), 3.03 (d, J = 13.5 Hz, 1 H), 2.86–2.80 (m, 2 H),  2.60 (d, J = 13.0 Hz, 1 H), 
2.53 (d, J = 13.5 Hz, 1 H), 2.06–2.03 (m, 1 H), 1.95–1.92 (m, 1 H), 1.80–1.77 (m, 2 H), 1.64–
1.54 (m, 2 H), 1.44–1.36 (m, 2 H), 1.26–1.23 (m, 1 H); 13C NMR (125 MHz, CDCl3) δ 174.6, 
143.5, 140.8, 138.9, 136.1, 130.4, 128.7, 128.6, 128.1, 128.0, 127.9, 127.7, 127.5, 126.7, 126.5, 
80.3, 80.1, 68.1, 50.4, 49.9, 42.4, 34.0, 31.9, 25.8, 24.6 (two carbon signals are absent due to 
incidental equivalence); IR (film) 3494, 2931, 1725 cm–1. MS (ESI) 520.2835 (520.2852 calcd 
for C35H37NO3, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
methyl ester (19) through reaction with NaOMe using General Procedure B. This procedure 
afforded 27 mg (62%) of 19. The enantiopurity of the methyl ester was determined to be 96% ee 
by chiral HPLC analysis (chiracel AD 0.46 cm x 15 cm, 10% isopropanol/ hexanes, 0.5 mL/min, 
RT= 23.9 and 28.4 min). 









(+)-(2R,3S)-Methyl-2-benzyl-3-benzylamino-2-hydroxy-3-phenylpropanoate (19). [α]23D 
+30.9 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.45–7.37 (m, 3 H), 7.37–7.27 (m, 4 H), 
7.24–7.16 (m, 6 H), 7.01–7.00 (m, 2 H), 3.90 (s, 1 H), 3.72 (s, br, 1 H), 3.69 (s, 3 H), 3.46 (s, 1 
H), 3.37 (d, J = 13.5 Hz, 1 H), 2.78 (d, J = 13.0 Hz, 1 H), 2.40–2.37  (m, 2 H); 13C NMR (125 
MHz, CDCl3) δ 175.6, 140.2, 138.4, 135.6, 128.8, 129.3, 128.4, 128.3, 128.1, 128.0, 127.8, 
126.9, 126.7, 81.7, 65.9, 52.5, 50.1, 43.2; IR (film) 3502, 3029, 1738 cm–1. MS (ESI) 376.1898 











3’-phenylpropanoate (5). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-
(benzyloxy)acetate (3a) (67 mg, 0.21 mmol) with N-(benzylidene)-4-methoxyaniline4 (66 mg, 
0.31 mmol) was conducted according to General Procedure A using triethylamine as base to 
afford 97 mg (87%) of the title compound as a white foam. The diastereoselectivity of the 
transformation could not be determined through 1H NMR analysis of the crude reaction mixture 
prior to purification due to signal overlap with boron-containing byproducts; the isolated product 
was obtained with 4:1 dr following purification. [α]23D –35.9 (c 0.20, CH2Cl2). 1H NMR (400 
MHz, CDCl3) δ 7.18–7.08 (m, 12 H), 7.04–7.02 (m, 3 H), 6.56–6.54 (m, 2 H), 6.13–6.11 (m, 2 
H), 4.96–4.90 (m, 1 H), 3.40 (s, br, 1 H), 4.13–4.11 (m, 1 H), 3.68 (s, 3 H), 3.31 (s, 1 H), 2.85–
2.78 (m, 2 H), 2.68–2.65 (m, 1 H), 2.00–1.90 (m, 2 H), 1.80–1.73 (m, 2 H), 1.54–1.44 (m, 2 H), 
1.40–1.23 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 174.1, 151.8, 142.6, 140.1, 138.2, 135.4, 
130.4, 128.6, 128.5, 128.0, 127.9, 127.4, 127.0, 126.8, 126.8, 115.6, 114.3, 79.6, 79.5, 62.9, 55.6, 
49.5, 42.7, 34.8, 31.9, 25.7, 24.6; IR (film) 3378, 2931, 1733 cm–1. MS (ESI) 558.2617 
(558.2620 calcd for C35H37NO4, M + Na+). 
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The enantiopurity of the title compound was assessed by conversion to the corresponding 
methyl ester (S1) through reaction with NaOMe using General Procedure B. The enantiopurity of 
the methyl ester was determined to be 58% ee by chiral HPLC analysis (chiracel AD 0.46 cm x 










(S1). [α]23D –4.6 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.45–7.43 (m, 2 H), 7.36–7.31 
(m, 2 H), 7.28–7.17 (m, 4 H), 7.07–7.04 (m, 2 H), 6.68–6.63 (m, 2 H), 6.55–6.52 (m, 2 H), 4.78 
(s, 1 H), 4.59 (s, 1 H), 3.71 (s, 3 H), 3.67 (s, 3 H), 3.41 (s, 1 H), 3.01 (d, J = 13.2 Hz, 1 H), 2.52 
(d, J = 13.2 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 175.0, 140.3, 138.1, 135.3, 129.8, 128.9, 
128.2, 128.1, 127.8, 126.9, 115.7, 114.6, 81.1, 63.6, 55.6, 53.0, 43.4, 27.0; IR (film) 3503, 2931, 











phenylpropanoate (6). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(benzyloxy)acetate 
(3a) (45 mg, 0.14 mmol) with N-benzylideneaniline4 (37 mg, 0.21 mmol) was conducted 
according to General Procedure A using triethylamine as base to afford 47 mg (67%) of the title 
compound as a white foam. The diastereoselectivity of the transformation could not be 
determined through 1H NMR analysis of the crude reaction mixture prior to purification due to 
signal overlap with boron-containing byproducts; the isolated product was obtained with 11:1 dr 
following purification. [α]23D –63.8 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.20–7.16 
(m, 8 H), 7.15–7.12 (m, 2 H), 7.10–7.07 (m, 2 H), 7.05–6.99 (m, 3 H), 6.98–6.93 (m, 2 H), 6.59–
6.53 (m, 1 H), 6.21–6.20 (m, 2 H), 4.96–4.91 (m, 1 H), 4.67 (d, J= 10.5 Hz, 1 H), 4.20 (d, J= 
10.0 Hz, 1 H), 3.29 (s, 1 H), 2.86 (s, 1 H), 2.84–2.79 (m, 1 H), 2.70–2.67 (m, 1 H), 1.99–1.91 (m, 
2 H), 1.79–1.74 (m, 2 H), 1.53–1.43 (m, 1 H), 1.40–1.33 (m, 2 H), 1.30–1.22 (m, 1 H); 13C NMR 
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(125 MHz, CDCl3) δ 174.0, 145.9, 142.5, 138.0, 135.2, 130.4, 128.7, 128.6, 128.0, 127.9, 127.5, 
127.0, 126.9, 126.8, 117.2, 114.3, 79.6, 79.5, 62.9, 49.5, 42.6, 34.7, 31.9, 25.7, 24.6 (one carbon 
signal is absent due to incidental equivalence); IR (film) 3396, 2924, 1717 cm–1. MS (ESI) 
528.2524 (528.2515 calcd for C34H35NO3, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S2) using General Procedure C. This procedure afforded 17 mg (57%) of S2. The 












methoxy-2-phenylpropanoate (S2). [α]23D –30.6 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) 
δ 7.54–7.52 (m, 2 H), 7.40–7.36 (m, 1 H), 7.34–7.29 (m, 3 H), 7.28–7.23 (m, 7 H), 7.07–6.97 
(m, 2 H), 6.99–6.97 (m, 1 H), 6.67–6.62 (m, 2 H), 6.50–6.48 (m, 2 H), 4.89–4.86 (m, 1 H), 4.57–
4.55 (m, 1 H), 4.41–4.38 (m, 1 H), 3.92–3.90 (m, 1 H), 3.57 (s, 3 H), 2.77 (d, J= 14.0 Hz, 1 H), 
2.56–2.53 (m, 1 H), 1.54 (s, 1 H); 19F NMR (376 MHz, (CD3)2CO) δ –70.9; IR (film) 3402, 










methoxyphenylpropanoate (7). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-
(benzyloxy)acetate (3a) (56 mg, 0.17 mmol) with N-(4-methoxybenzylidene)benzylamine1 (58 
mg, 0.26 mmol) was conducted according to General Procedure A using triethylamine as base to 
afford 87 mg (93%) of the title compound as a colorless oil. The diastereoselectivity of the 
transformation could not be determined through 1H NMR analysis of the crude reaction mixture 
prior to purification due to signal overlap with boron-containing byproducts; the isolated product 
was obtained with 20:1 dr following purification. [α]23D –32.0 (c 0.10, CH2Cl2). 1H NMR (500 
MHz, CDCl3) δ 7.30–7.23 (m, 5 H), 7.20–7.09 (m, 9 H), 7.08–7.04 (m, 1 H), 6.98–6.96 (m, 2 H), 
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6.82–6.80 (m, 2 H), 4.81–4.76 (m, 1 H), 3.80 (s, 3 H), 3.45 (s, 1 H), 3.26 (s, 1 H), 3.04 (d, J = 
13.5 Hz, 1 H), 2.85–2.79 (m, 2 H), 2.60 (d, J = 13.5 Hz, 1 H), 2.55 (d, J = 14.0 Hz, 1 H), 2.06–
2.03 (m, 1 H), 1.94–1.92 (m, 1 H), 1.79–1.73 (m, 2 H), 1.63–1.54 (m, 1 H), 1.44–1.35 (m, 2 H), 
1.31–1.20 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 174.7, 158.9, 143.5, 140.8, 136.2, 130.9, 
130.4, 129.7, 128.6, 128.0, 127.9, 127.7, 127.5, 126.7, 126.5, 126.4, 113.5, 80.4, 80.0, 67.4, 55.2, 
50.4, 49.8, 42.3, 34.0, 31.9, 25.9, 24.6; IR (film) 3494, 2934, 1725 cm–1. MS (ESI) 572.2778 
(572.2777 calcd for C36H39NO4, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
methyl ester (S3) through reaction with NaOMe using General Procedure B. This procedure 
afforded 20 mg (55%) of S3. The enantiopurity of the methyl ester was determined to be 90% ee 
by chiral HPLC analysis (chiracel AD 0.46 cm x 15 cm, 5% isopropanol/ hexanes, 0.2 mL/min, 










(S3). [α]23D +28.0 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.34–7.31 (m, 2 H), 7.28–7.27 
(m, 2 H), 7.23–7.20 (m, 2 H), 7.19–7.15 (m, 4 H), 7.01–6.99 (m, 2 H), 6.95–6.93 (m, 2 H), 3.88 
(s, 1 H), 3.84 (s, 3 H), 3.71 (s, 1 H), 3.68 (s, 3 H), 3.64 (s, 1 H), 3.45–3.34 (m, 2 H), 2.75 (d, J = 
13.2 Hz, 1 H), 2.39 (d, J = 13.2 Hz, 1 H); 13C NMR (125 MHz, CDCl3) δ 175.7, 159.2, 140.3, 
135.8, 130.5, 130.3, 129.8, 128.4, 128.0, 126.8, 126.7, 113.7, 81.8, 65.3, 55.2, 52.4, 50.0, 43.2 
(one carbon signal is absent due to incidental equivalence); IR (film) 3498, 3035, 1730 cm–1. MS 











hydroxypropanoate (8). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(benzyloxy)acetate 
(3a) (52 mg, 0.16 mmol) with N-(furylidene)benzylamine,1 (45 mg, 0.24 mmol) was conducted 
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according to General Procedure A using triethylamine as base to afford 56 mg (68%) of the title 
compound as a white foam. The diastereoselectivity of the transformation could not be 
determined through 1H NMR analysis of the crude reaction mixture prior to purification due to 
signal overlap with boron-containing byproducts; the isolated product was obtained with 20:1 dr 
following purification. [α]23D –9.5 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.35–7.32 (m, 
1 H), 7.31–7.23 (m, 3 H), 7.22–7.18 (m, 7 H), 7.17–7.09 (m, 4 H), 7.05–7.02 (m, 1 H), 6.30–6.29 
(m, 1 H), 6.09–6.07 (m, 1 H), 4.85–4.80 (m, 1 H), 3.49 (s, 1 H), 3.45 (s, 1 H), 3.12 (d, J = 13.0 
Hz, 1 H), 2.93 (d, J = 14.0 Hz, 1 H), 2.83–2.78 (m, 1 H), 2.69–2.65 (m, 2 H), 2.07–2.04 (m, 1 
H), 1.94–1.90 (m, 1 H), 1.81–1.76 (m, 2 H), 1.60–1.47 (m, 2 H), 1.47–1.33 (m, 2 H), 1.32–1.24 
(m, 1 H); 13C NMR (125 MHz, CDCl3) δ 174.0, 153.0, 143.3, 141.9, 140.5, 135.8, 130.4, 128.6, 
128.0, 127.9, 127.8, 127.4, 126.6, 126.5, 110.0, 108.7, 79.9, 79.8, 61.9, 50.6, 49.7, 41.8, 34.3, 
31.9, 25.8, 24.6 (two carbon signals are absent due to incidental equivalence); IR (film) 3420, 
2935, 1728 cm–1. MS (ESI) 510.2639 (510.2644 calcd for C33H35NO4, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S4) using General Procedure C. This procedure afforded 6 mg (43%) of S4. The 












methoxy-2-phenylpropanoate (S4). [α]23D –11.6 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) 
δ 7.56–7.53 (m, 2 H), 7.44–7.43 (m, 1 H), 7.42–7.33 (m, 3 H), 7.29–7.27 (m, 2 H), 7.25–7.18 
(m, 6 H), 7.14–7.12 (m, 2 H), 6.37–6.36 (m, 1 H), 6.04–6.03 (m, 1 H), 4.37–4.35 (m, 1 H), 3.90–
3.85 (m, 3 H), 3.70–3.69 (m, 1 H), 3.45 (s, 3 H), 3.41–3.39 (m, 2 H), 2.75–2.72 (m, 1 H), 2.61–
2.58 (m, 1 H); 19F NMR (376 MHz, (CD3)2CO) δ –71.5; IR (film) 3376, 2936, 1751 cm–1. MS 
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(–)-(1R,2S,2’R,3’S)-2-Phenylcyclohexyl-2’-benzyl-3’-benzylamino-3’-cyclohexyl-2’-
hydroxypropanoate (9). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(benzyloxy)acetate 
(3a) (43 mg, 0.13 mmol) with N-(cyclohexylmethylidene)benzylamine5 (54 mg, 0.27 mmol, 2 
equiv) was conducted according to General Procedure A using triethylamine as base to afford 46 
mg (66%) of the title compound as a yellow oil. The diastereoselectivity of the transformation 
could not be determined through 1H NMR analysis of the crude reaction mixture prior to 
purification due to signal overlap with boron-containing byproducts; the isolated product was 
obtained with >20:1 dr following purification. [α]23D –4.6 (c 0.10, CH2Cl2). 1H NMR (500 MHz, 
CDCl3) δ 7.37–7.35 (m, 2 H), 7.30–7.27 (m, 2 H), 7.25–7.19 (m, 6 H), 7.18–7.14 (m, 5 H), 4.58–
4.53 (m, 1 H), 4.08 (s, 1 H), 3.03 (d, J = 13.5 Hz, 1 H), 2.95 (d, J = 14.0 Hz, 1 H), 2.86 (d, J = 
12.5 Hz, 1 H), 2.71–2.64 (m, 2 H), 2.20 (s, 1 H), 1.89–1.86 (m, 1 H), 1.78–1.64 (m, 6 H), 1.62–
1.60 (m, 3 H), 1.42–1.40 (m, 1 H), 1.35–1.25 (m, 3 H), 1.22–1.10 (m, 3 H), 1.06–0.88 (m, 3 H); 
13C NMR (125 MHz, CDCl3) δ 175.2, 143.5, 141.1, 136.9, 130.3, 128.5, 128.2, 128.1, 127.9, 
126.8, 126.7, 126.4, 79.6, 79.4, 67.5, 53.9, 49.7, 41.4, 38.8, 33.3, 32.5, 31.6, 27.0, 26.7, 26.3, 
25.7, 24.5; IR (film) 3382, 2924, 1724 cm–1. MS (ESI) 526.3333 (526.3321 calcd for C35H43NO3, 
M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S5) using General Procedure C. This procedure afforded 15 mg (71%) of S5. The 












2-methoxy-2-phenylpropanoate (S5). [α]23D +42.8 (c 0.20, CH2Cl2). 1H NMR (400 MHz, 
CDCl3) δ 7.56–7.54 (m, 2 H), 7.43–7.39 (m, 4 H), 7.34–7.29 (m, 4 H), 7.24–7.20 (m, 3 H), 7.15–
7.13 (m, 2 H), 4.11–4.09 (m, 1 H), 3.88–3.80 (m, 2 H), 3.63–3.59 (m, 2 H), 3.53 (s, 3 H), 2.84–
2.80 (m, 1 H), 2.64–2.61 (m, 2 H), 1.75–1.67 (m, 6 H), 1.30–1.22 (m, 6 H); 19F NMR (376 MHz, 
(CD3)2CO) δ –71.0; IR (film) 3358, 2932, 1754 cm–1. MS (ESI) 570.2850 (570.2831 calcd for 
C33H38F3NO4, M + Na+). 
 









(10). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(allyloxy)acetate (3b) (46 mg, 0.17 
mmol) with N-(benzylidene)benzylamine1 (49 mg, 0.25 mmol) was conducted according to 
General Procedure A using diisopropylethylamine as base to afford 78 mg (70%) of the title 
compound as a white foam. The diastereoselectivity of the transformation could not be 
determined through 1H NMR analysis of the crude reaction mixture prior to purification due to 
signal overlap with boron-containing byproducts; the isolated product was obtained with >20:1 
dr following purification. [α]23D –36.7 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.28–7.21 
(m, 7 H), 7.21–7.14 (m, 3 H), 7.10–7.08 (m, 2 H), 7.07–7.04 (m, 3 H), 5.44–5.37 (m, 1 H), 4.96–
4.90 (m, 3 H), 3.38–3.36 (m, 2 H), 3.10 (d, J = 13.5 Hz, 1 H), 2.83–2.77 (m, 1 H), 2.71 (d, J = 
13.5 Hz, 1 H), 2.40–2.32 (m, 2 H), 1.96–1.93 (m, 1 H), 1.89–1.79 (m, 3 H), 1.67–1.49 (m, 3 H), 
1.42–1.33 (m, 2 H); 13C NMR (125 MHz, CDCl3) δ 174.5, 143.4, 140.6, 138.8, 131.9, 128.6, 
128.1, 128.0, 127.9, 127.5, 127.4, 126.7, 126.6, 118.8, 79.8, 79.3, 67.6, 50.5, 49.7, 41.4, 34.1, 
32.2, 25.8, 24.6 (one carbon signal is absent due to incidental equivalence); IR (film) 3494, 2935, 
1727 cm–1. MS (ESI) 492.2903 (492.2515 calcd for C31H35NO3, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S6) using General Procedure C. This procedure afforded 16 mg (41%) of S6. The 










phenylpropanoate (S6).  [α]23D +11.0 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.60–7.56 
(m, 2 H), 7.44–7.40 (m, 3 H), 7.37–7.29 (m, 5 H), 7.27–7.23 (m, 4 H), 7.15–7.13 (m, 1 H), 5.86–
5.75 (m, 1 H), 5.10–5.08 (m, 1 H), 5.01–4.95 (m, 1 H), 4.55 (d, J = 11.2 Hz, 1 H), 3.90 (d, J = 
11.6 Hz, 1 H), 3.75 (s, 1 H), 3.64 (d, J = 13.2 Hz, 1 H), 3.51 (s, 3 H), 3.38 (d, J = 13.2 Hz, 1 H), 
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3.23 (s, br, 1 H), 2.20–2.15 (m, 2 H), 1.97–1.92 (m, 1 H); 19F NMR (376 MHz, (CD3)2CO) δ –










hydroxypent-4-enoate (11). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-
(allyloxy)acetate (3b) (49 mg, 0.18 mmol) with N-(4-fluorophenylmethylidine)benzylamine1 (57 
mg, 0.27 mmol) was conducted according to General Procedure A using diisopropylethylamine 
as base to afford 59 mg (68%) of the title compound as a white foam. The diastereoselectivity of 
the transformation could not be determined through 1H NMR analysis of the crude reaction 
mixture prior to purification due to signal overlap with boron-containing byproducts; the isolated 
product was obtained with >20:1 dr following purification. [α]23D –25.8 (c 0.10, CH2Cl2). 1H 
NMR (500 MHz, CDCl3) δ 7.27–7.20 (m, 5 H), 7.19–7.14 (m, 2 H), 7.09–7.05 (m, 3 H), 6.98–
6.91 (m, 4 H), 5.44–5.36 (m, 1 H), 4.98–4.91 (m, 3 H), 3.36–3.32 (m, 2 H), 3.09 (d, J = 13.0 Hz, 
1 H), 2.82–2.76 (m, 1 H),  2.72 (d, J = 13.0 Hz, 1 H), 2.38–2.32 (m, 2 H), 1.96–1.93 (m, 1 H), 
1.89–1.79 (m, 3 H), 1.65–1.59 (m, 2 H), 1.57–1.48 (m, 1 H), 1.42–1.33 (m, 2 H); 13C NMR (125 
MHz, CDCl3) δ 174.4, 163.4, 161.0, 143.4, 140.4, 134.5, 134.4, 131.7, 130.1, 128.6, 128.0, 
127.4, 126.7, 118.9, 115.0 (d, J= 26.6 Hz), 79.7, 79.5, 67.9, 50.4, 49.7, 41.4, 34.1, 32.2, 25.8, 
24.6; IR (film) 3366, 2931, 1730 cm–1. MS (ESI) 488.2595 (488.2601 calcd for C31H34FNO3, M + 
Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S7) using General Procedure C. This procedure afforded 27 mg (50%) of S7. The 










                                                                                                                                                      S 13 
(+)-(2S,3’R,4’S)-3’-Allyl-4’-benzylamino-4’-(p-fluorophenyl)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoate (S7).  [α]23D +5.0 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.56–7.49 
(m, 2 H), 7.45–7.36 (m, 3 H), 7.31–7.24 (m, 3 H), 7.21–7.16 (m, 3 H), 7.11–7.07 (m, 1 H), 7.02–
6.95 (m, 2 H), 5.82–5.71 (m, 1 H), 5.10–5.09 (m, 1 H), 5.00–4.96 (m, 1 H), 4.54 (t, J = 11.6 Hz, 
1 H), 4.04 (d, J = 11.2 Hz, 0.5 H), 3.90 (d, J = 14.5 Hz, 0.5 H), 3.72 (s, 1 H), 3.61–3.56 (m, 2 
H), 3.50 (s, 3 H), 3.39–3.32 (m, 1 H), 2.19–2.11 (m, 1 H), 1.98–1.85 (m, 2 H); 19F NMR (376 
MHz, (CD3)2CO) δ –71.3; IR (film) 3386, 2929, 1750 cm–1. MS (ESI) 532.2110 (532.2111 calcd 











carboxylate (13). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(benzyloxy)acetate (3a) 
(56 mg, 0.18 mmol) with N-(tert-butoxycarbonyl)benzylamine2 (55 mg, 0.27 mmol) was 
conducted according to General Procedure A using triethylamine as base to afford 52 mg (97%) 
of the title compound as a white foam. The diastereoselectivity of the transformation could not 
be determined through 1H NMR analysis of the crude reaction mixture prior to purification due 
to signal overlap with boron-containing byproducts; the isolated product was obtained with 
>20:1 dr following purification. [α]23D –64.0 (c 0.20, CH2Cl2). 1H NMR (500 MHz, CDCl3) 
δ 7.37–7.29 (m, 7 H), 7.23–7.14 (m, 4 H), 7.12–7.08 (m, 2 H), 7.00–6.98 (m, 2 H), 5.16–5.11 
(m, 1 H), 5.03 (s, 1 H), 3.69 (s, 1 H), 2.85–2.80 (m, 1 H),  2.45 (d,  J= 15.0 Hz, 1 H), 2.33 (d, J = 
15.0 Hz, 1 H), 2.00–1.98 (m, 1 H), 1.84–1.78 (m, 3 H), 1.56–1.48 (m, 1 H), 1.45–1.32 (m, 3 H); 
13C NMR (125 MHz, CDCl3) δ 169.1, 158.1, 143.1, 135.8, 134.1, 129.9, 129.1, 128.9, 128.8, 
128.0, 127.4, 127.2, 127.1, 86.5, 62.1, 50.4, 39.4, 34.8, 31.9, 25.7, 24.7 (two carbon signals are 
absent due to incidental equivalence); IR (film) 3270, 2935, 1766 cm–1. MS (ESI) 478.2001 
(478.1994 calcd for C29H29NO4, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S8) using General Procedure C. This procedure afforded 16 mg (64%) of S8. The 
enantiopurity was determined to be 94% ee by 19F NMR analysis. 













methoxy-2-phenylpropanoate (S8).  [α]23D +8.5 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) 
δ 7.57–7.56 (m, 2 H), 7.48–7.30 (m, 7 H), 7.25–7.15 (m, 4 H), 7.03–7.00 (m, 2 H), 5.31 (s, 1 H), 
4.79 (s, 1 H), 4.28 (d, J = 11.6 Hz, 1 H), 4.17 (d, J = 12.0 Hz, 1 H), 3.56 (s, 3 H), 2.59 (d, J = 
14.8 Hz, 1 H), 2.12 (d, J = 14.4 Hz, 1 H); 19F NMR (376 MHz, (CD3)2CO) δ –71.1; IR (film) 









(–)-(1R,2S,2’R,3’S)-2-Phenylcyclohexyl-2’-allyl-2’-oxo-3’-phenyloxazolidine (14). The 
reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-(allyloxy)acetate (3b) (47 mg, 0.17 mmol) with 
N-(tert-butoxycarbonyl)benzylamine2 (53 mg, 0.26 mmol) was conducted according to General 
Procedure A using diisopropylethylamine as base to afford 45 mg (62%) of the title compound as 
a colorless oil. The diastereoselectivity of the transformation could not be determined through 1H 
NMR analysis of the crude reaction mixture prior to purification due to signal overlap with 
boron-containing byproducts; the isolated product was obtained with >20:1 dr following 
purification. [α]23D –6.1 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.35–7.30 (m, 7 H), 
7.22–7.17 (m, 1 H), 6.99–6.97 (m, 2 H), 5.42–5.32 (m, 1 H), 5.26–5.20 (m, 1 H), 5.09 (s, 1 H), 
4.91–4.83 (m, 2 H), 3.95 (s, 1 H), 2.86–2.80 (m, 1 H), 2.19–2.16 (m, 1 H), 2.06–2.00 (m, 1 H), 
1.99–1.89 (m, 2 H), 1.85–1.81 (m, 1 H), 1.75–1.63 (m, 1 H), 1.60–1.34 (m, 4 H); 13C NMR (125 
MHz, CDCl3) δ 169.6, 143.0, 135.7, 130.0, 129.1, 128.8, 127.5, 127.1, 126.6, 119.8, 86.1, 77.8, 
61.7, 50.1, 38.1, 34.6, 32.1, 25.7, 24.7 (two carbon signals are absent due to incidental 
equivalence); IR (film) 3295, 2934, 1766 cm–1. MS (ESI) 428.1829 (428.1838 calcd for 
C25H27NO4, M + Na+). 
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The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S9) using General Procedure C. This procedure afforded 71 mg (53%) of S9. The 











phenylpropanoate (S9). [α]23D +9.0 (c 0.10, CH2Cl2).  1H NMR (500 MHz, CDCl3) δ 7.58–7.56 
(m, 2 H), 7.47–7.44 (m, 3 H), 7.41–7.35 (m, 3 H), 7.16–7.14 (m, 2 H), 5.62–5.55 (m, 1 H), 5.35  
(s, 1 H), 5.07 (d, J = 10.5 Hz, 1 H), 4.91–4.88 (m, 1 H), 4.74 (s, 1 H), 4.49 (d, J = 12.0 Hz, 1 H), 
4.41 (d, J = 11.5 Hz, 1 H), 3.58 (s, 3 H), 2.10–2.06 (m, 1 H), 1.72–1.67 (m, 1 H); 19F NMR (376 
MHz, (CD3)2CO) δ –71.3; IR (film) 3273, 2926, 1760 cm–1. MS (ESI) 472.1336 (472.1348 calcd 











hydroxy-3’-phenylpropanoate (16). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-
(benzyloxy)acetate (3a) (53 mg, 0.16 mmol) with N-tert-butoxycarbonyl-α-
(phenylsulfonyl)benzylamine2 (85 mg, 0.25 mmol) was conducted according to General 
Procedure A using diisopropylethylamine as base to afford 50 mg (58%) of the title compound as 
a white solid, m.p. 160–162 °C. The diastereoselectivity of the transformation could not be 
determined through 1H NMR analysis of the crude reaction mixture prior to purification due to 
signal overlap with boron-containing byproducts; the isolated product was obtained with >20:1 
dr following purification. [α]23D –8.0 (c 0.20, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.46–7.38 
(m, 1 H), 7.31–7.27 (m, 3 H), 7.22–7.21 (m, 3 H), 7.15–7.13 (m, 5 H), 7.08–7.06 (m, 2 H), 6.43–
6.41 (m, 1 H), 5.49–5.46 (m, 1 H), 4.89–4.84 (m, 1 H), 4.65–4.63 (m, 1 H), 3.12–3.08 (m, 1 H), 
3.03–3.00 (m, 1 H), 2.98 (s, 1 H), 2.92–2.86 (m, 1 H), 2.03–2.00 (m, 1 H), 1.91–1.88 (m, 1 H), 
1.81–1.63 (m, 1 H), 1.58 (s, 1 H), 1.53 (s, 9 H), 1.45–1.35 (m, 2 H), 1.30–1.21 (m, 2 H); 13C 
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NMR (125 MHz, CDCl3) δ 173.3, 154.7, 143.1, 137.5, 135.2, 130.6, 129.2, 127.9, 127.8, 127.6, 
127.5, 127.4, 126.9, 80.9, 79.5, 60.0, 49.2, 33.8, 31.8, 28.5, 24.5 (four carbon signals are absent 
due to incidental equivalence); IR (film) 3429, 2934, 1718 cm–1. MS (ESI) 552.2718 (552.2726 
calcd for C33H39NO5, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S10) using General Procedure C. This procedure afforded 21.3 mg (51%) of S10. 














3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (S10). [α]23D –26.0 (c 0.20, CH2Cl2). 1H NMR 
(400 MHz, CDCl3) δ 7.67–7.66 (m, 2 H), 7.52–7.46 (m, 3 H), 7.36–7.29 (m, 5 H), 7.21–7.16 (m, 
3 H), 6.84–6.81 (m, 2 H), 5.58–5.55 (m, 1 H), 4.82–4.80 (m, 1 H), 4.23 (d, J = 11.2 Hz, 1 H), 
3.70 (s, 3 H), 3.67–3.60 (m, 1 H), 2.72–2.69 (m, 1 H), 2.39–2.36 (m, 1 H), 1.54 (s, 1 H), 1.40 (s, 
9 H); 19F NMR (376 MHz, (CD3)2CO) δ –70.9; IR (film) 3432, 2932, 1752 cm–1. MS (ESI) 













hydroxy-5’-methylhexanoate (17). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-
(benzyloxy)acetate (3a) (49 mg, 0.15 mmol) with N-tert-butoxycarbonyl-3-methyl-1-
(phenylsulfonyl)butylcarbamate3 (75 mg, 0.23 mmol) was conducted according to General 
Procedure A using diisopropylethylamine as base to afford 62 mg (81%) of the title compound as 
a white foam. The diastereoselectivity of the transformation could not be determined through 1H 
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NMR analysis of the crude reaction mixture prior to purification due to signal overlap with 
boron-containing byproducts; the isolated product was obtained with 20:1 dr following 
purification. [α]23D –6.8 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.38–7.35 (m, 3 H), 
7.30–7.26 (m, 2 H), 7.25–7.19 (m, 5 H), 4.94–4.88 (m, 1 H), 3.92–3.90 (m, 1 H), 3.58–3.54 (m, 
1 H), 3.27–3.20 (m, 1 H), 3.12 (d, J = 13.5 Hz, 1 H), 2.92  (d, J = 14.0 Hz, 1 H), 2.88–2.83 (m, 1 
H), 2.06–2.03 (m, 1 H), 1.99–1.97 (m, 1 H), 1.86–1.82 (m, 1 H), 1.81–1.77 (m, 1 H), 1.57–1.54 
(m, 2 H), 1.53 (s, 9 H), 1.41–1.37 (m, 5 H), 0.74–0.72 (m, 3 H), 0.67–0.66 (m, 3 H); 13C NMR 
(125 MHz, CDCl3) δ 174.1, 155.8, 143.4, 135.8, 130.6, 129.4, 127.8, 127.3, 126.7, 80.2, 79.6, 
78.9, 54.7, 49.7, 41.6, 37.8, 34.6, 32.2, 28.5, 28.4, 25.6, 24.7, 23.3, 20.9 (one carbon signal is 
absent due to incidental equivalence); IR (film) 3420, 2923, 1718 cm–1. MS (ESI) 532.3027 
(532.3039 calcd for C31H43NO5, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S11) using General Procedure C. This procedure afforded 12.2 mg (53%) of S11. 








F3C OMe  
(–)-(1S,2’R,3’R)-2’-Benzyl-3’-[(tert-butoxycarbonyl)amino]-2’-hydroxy-5’-methylhexyl-
3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (S11). [α]23D –28.0 (c 0.10, CH2Cl2). 1H NMR 
(400 MHz, CDCl3) δ 7.58–7.53 (m, 2 H), 7.41–7.40 (m, 3 H), 7.20–7.19 (m, 3 H), 7.04–7.03 (m, 
2 H), 4.48–4.42 (m, 1 H), 4.09–4.05 (m, 1 H), 3.90–3.87 (m, 1 H), 3.71–3.63 (m, 1 H), 3.57 (s, 3 
H), 3.52 (s, 1 H), 2.91 (s, 1 H), 2.80–2.76 (m, 1 H), 2.69–2.65 (m, 1 H), 1.50 (s, 2 H), 1.39 (s, 9 
H), 0.88 (d, J = 6.8 Hz, 3 H), 0.78 (d, J = 6.4 Hz, 3 H); 19F NMR (376 MHz, (CD3)2CO) δ –70.9; 
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(–)-(1R,2S,2’R,3’R)-2-Phenylcyclohexyl-3’-[(tert-butoxycarbonyl)amino]-3’-cyclohexyl-2’-
hydroxypent-4-enoate (18). The reaction of (–)-(1R,2S)-2-phenylcyclohexyl-2’-
(benzyloxy)acetate (3b) (44 mg, 0.16 mmol) with N-tert-butoxycarbonyl-α-
cyclohexyl(phenylsulfonyl)methylcarbamate3 (85 mg, 0.24 mmol) was conducted according to 
General Procedure A using diisopropylethylamine as base to afford 49 mg (63%) of the title 
compound as a colorless oil. The diastereoselectivity of the transformation could not be 
determined through 1H NMR analysis of the crude reaction mixture prior to purification due to 
signal overlap with boron-containing byproducts; the isolated product was obtained with 20:1 dr 
following purification. [α]23D –21.4 (c 0.20, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.38–7.31 
(m, 2 H), 7.29–7.24 (m, 2 H), 7.20–7.16 (m, 1 H), 5.52–5.46 (m, 1 H), 5.08–5.02 (m, 3 H), 4.89–
4.83 (m, 1 H), 4.61 (d, J = 11.0 Hz, 1 H), 3.22 (s, 1 H), 2.80–2.75 (m, 1 H), 2.52–2.48 (m, 1 H), 
2.35–2.25 (m, 3 H), 1.98–1.95 (m, 1 H), 1.89–1.86 (m, 1 H), 1.82–1.79 (m, 2 H), 1.72–1.70 (m, 
1 H), 1.66–1.60 (m, 2 H), 1.54 (s, 9 H), 1.44–1.38 (m, 7 H), 1.38–1.26 (m, 3 H); 13C NMR (125 
MHz, CDCl3) δ 175.3, 155.6, 143.3, 131.4, 129.0, 127.6, 127.2, 119.8, 80.5, 78.9, 60.2, 49.5, 
42.3, 36.9, 33.9, 32.0, 31.3, 28.5, 26.2, 25.9, 25.7, 25.3, 24.5; IR (film) 3420, 2923, 1718 cm–1. 
MS (ESI) 508.3029 (508.3039 calcd for C29H43NO5, M + Na+). 
The enantiopurity of the title compound was assessed by conversion to the corresponding 
Mosher ester (S12) using General Procedure C. This procedure afforded 13.4 mg (67%) of S12. 










3,3,3-trifluoro-2-methoxy-2-phenylpropanoate (S12). [α]23D –48.0 (c 0.20, CH2Cl2). 1H NMR 
(400 MHz, CDCl3) δ 7.56–7.52 (m, 2 H), 7.44–7.40 (m, 3 H), 5.75–5.65 (m, 1 H), 5.19–5.12 (m, 
1 H), 4.91–4.88 (m, 1 H), 4.23–4.11 (m, 1 H), 3.56 (s, 3 H), 3.53–3.50 (m, 1 H), 2.31–2.29 (m, 2 
H), 2.04 (s, 1 H), 1.88–1.81 (m, 1 H), 1.74–1.71 (m, 3 H), 1.68–1.61 (m, 1 H), 1.40 (s, 9 H), 
1.23–1.14 (m, 4 H), 1.13–1.04 (m, 2 H), 1.00–0.88 (m, 1 H), 0.86–0.84 (m, 1 H); 19F NMR (376 
MHz, (CD3)2CO) δ –71.4; IR (film) 3398, 2923, 1719 cm–1. MS (ESI) 552.2542 (552.2549 calcd 
for C27H38F3NO6, M + Na+). 








(+)-(1S,2R)-3-Benzylamino-3-(p-fluorophenyl)-2-hydroxypent-4-ene-1-ol (20). The reaction 
of (–)-(1R,2S,2’R,3’S)-2-Phenylcyclohexyl-3’-benzylamino-3’-(p-fluorophenyl)-2’-hydroxypent-
4-enoate (11) (49 mg, 0.10 mmol) with lithium aluminum hydride (0.20 mL, 0.20 mmol, 1 M in 
THF) was conducted according to General Procedure C to afford 31 mg (97%) of the title 
compound as an oil. [α]23D +14.8 (c 0.10, CH2Cl2). 1H NMR (500 MHz, CDCl3) δ 7.37–7.32 (m, 
4 H), 7.28–7.26 (m, 2 H), 7.23–7.13 (m, 1 H), 7.09–6.96 (m, 2 H), 5.70–5.65 (m, 1 H), 5.02–5.00 
(m, 1 H), 4.92–4.89 (m, 1 H), 3.66–3.61 (m, 3 H), 3.56–3.55 (m, 1 H), 3.46–3.42 (m, 1 H), 2.08–
1.94 (m, 2 H), 1.84–1.77 (m, 2 H), 1.60 (s, br, 1 H); 13C NMR (125 MHz, CDCl3) δ 132.5, 130.2, 
128.7, 128.4, 127.9, 127.5, 118.9, 115.4 (d, J= 26.6 Hz), 74.3, 69.5, 67.7, 62.1, 50.9, 40.5, 25.7; 








(+)-(1S,2R)-2-Allyl-2-hydroxymethyl-1-phenyloxazolidin-2-one (21). The reaction of (–)-
(1R,2S,2’R,3’S)-2-Phenylcyclohexyl-2’-allyl-2’-oxo-3’-phenyloxazolidine (14) (34 mg, 0.08 
mmol) with lithium aluminum hydride (0.17 mL, 0.17 mmol, 1 M in THF) was conducted 
according to General Procedure C to afford 13 mg (65%) of the title compound as an oil. [α]23D 
+45.0 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.42–7.34 (m, 3 H), 7.33–7.27 (m, 2 H), 
5.60–5.49 (m, 1 H), 5.44, (s, br, 1 H), 5.16 (s, 1 H), 5.01–4.99 (m, 1 H), 4.91–4.87 (m, 1 H), 3.91 
(d, J= 12.4 Hz, 1 H), 3.63 (d, J= 12.4 Hz, 1 H), 2.32 (s, br, 1 H), 2.21–2.04 (m, 1 H), 1.76–1.67 
(m, 1 H); 13C NMR (125 MHz, CDCl3) δ 176.0, 158.2, 136.3, 131.3, 128.9, 127.1, 119.5, 86.9, 
64.9, 60.0, 37.7; IR (film) 3307, 2930, 1748 cm–1. MS (ESI) 233.1059 (233.1052 calcd for 
C13H15NO3, M + Na+). 
 








(+)-(1R,2R)-[(tert-Butoxycarbonyl)amino]-2-benzyl-1-phenylpropane-2,3-diol (22). The 
reaction of (–)-(1R,2S,2’R,3’R)-2-Phenylcyclohexyl-2’-benzyl-3’-[(tert-butoxycarbonyl)amino]-
2’-hydroxy-3’-phenylpropanoate (16) (50 mg, 0.10 mmol) with lithium aluminum hydride (0.38 
mL, 0.38 mmol, 1 M in THF) was conducted according to General Procedure C to afford 26 mg 
(77%) of the title compound as an oil. [α]23D +16.4 (c 0.10, CH2Cl2). 1H NMR (400 MHz, CDCl3) 
δ 7.48–7.45 (m, 2 H), 7.41–7.32 (m, 4 H), 7.29–7.27 (m, 1 H), 7.25–7.22 (m, 1 H), 7.14–7.13 
(m, 2 H), 5.40–5.38 (m, 1 H), 4.85–4.83 (m, 1 H), 3.57–3.55 (m, 1 H), 3.40–3.36 (m, 1 H), 3.18–
3.13 (m, 1 H), 2.97–2.94 (m, 1 H), 2.29–2.26 (m, 1 H), 1.63 (s, 1 H), 1.45 (s, 9 H); 13C NMR 
(125 MHz, CDCl3) δ 157.0, 138.4, 135.9, 130.6, 128.9, 128.6, 128.5, 127.9, 126.8, 80.5, 62.9, 
58.4, 40.1, 28.3 (one carbon signal is absent due to incidental equivalence); IR (film) 3412, 2924, 
1684 cm–1. MS (ESI) 380.1842 (380.1838 calcd for C21H27NO4, M + Na+). 
 
 
Assignment of Stereochemistry 
Stereochemical Assignment of (4). Stereochemical assignment of 4 was accomplished by 
single-crystal x-ray analysis of product that had been recrystallized from 
dichloromethane/hexanes. The ORTEP of 4 indicated this material had the 1R,2S,2’R,3’S 
stereochemical configuration. The data for 4 (CCDC 763869) can be obtained free of charge 
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Stereochemical Analysis of Amino Alcohol (16). Amino alcohol 16 was converted to 
derivative (S13) via deprotection of the Boc group followed by conversion to the oxazolidin-2-












































carboxylate (S13).  A flame-dried flask was charged with amino alcohol 16 (32 mg, 0.06 mmol, 
1.0 equiv) in dichloromethane (0.6 mL) and cooled to 0 °C. Trifluoroacetic acid (0.6 mL) was 
added dropwise, and the resulting solution was warmed to rt and stirred until the starting material 
had been completely consumed judged by TLC analysis (ca 1 h). Aqueous sodium carbonate (1.5 
mL) and dichloromethane (8 mL) were added, and the resulting mixture was transferred to a 
separatory funnel. The layers were separated, and the organic layer was dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The crude product (24 mg, 0.06 mmol, 94%) 
was added as a solution in acetonitrile (0.6 mL) to a flame dried two-neck flask fitted with a 
reflux condenser. Carbonyldiimidazole (10 mg, 0.06 mmol, 1.1 equiv) was added and the 
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reaction mixture was heated to reflux until the starting material was completely consumed as 
judged by TLC analysis (ca 14 h). The reaction mixture was cooled to rt and concentrated in 
vacuo. The crude residue was diluted with H2O (1 mL/mmol substrate), and extracted with 
dichloromethane (3 x 3 mL/mmol substrate). The phases were separated and the combined 
organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. 
The crude product was purified by flash chromatography on silica gel affording 22 mg (84%) of 
the title compound as a white foam. [α]23D –36.2 (c 0.1, CH2Cl2). 1H NMR (400 MHz, CDCl3) 
δ 7.36–7.28 (m, 5 H), 7.24–7.21 (m, 5 H), 7.20–7.09 (m, 5 H), 4.97–4.93 (m, 1 H), 3.54 (s, 1 H), 
3.40 (s, 1 H), 2.85–2.78 (m, 1 H), 2.68 (d, J = 14.0 Hz, 1 H), 2.28 (d, J = 13.6 Hz, 1 H), 2.03–
1.91 (m, 2 H), 1.84–1.78 (m, 3 H), 1.63–1.52 (m, 2 H), 1.49–1.34 (m, 1 H); 13C NMR (125 MHz, 
CDCl3) δ 174.4, 143.4, 141.4, 136.1, 130.1, 128.7, 128.3, 127.8, 127.6, 127.0, 126.6, 80.7, 79.0, 
61.4, 50.2, 42.3, 34.1, 32.3, 25.7, 24.7, 24.4, 24.1, 21.0; IR (film) 3391, 2932, 1734 cm–1. MS 
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